ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Hold" by Brokerages
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) has received an average "Hold" recommendation from five brokerages, with two analysts rating it a "sell" and three a "buy," and an average one-year price target of $30.67. The stock opened at $9.00, down 4.7%, with a market capitalization of $889.65 million. Institutional investors own 68.16% of the stock, with several firms increasing or initiating positions in Q4.
CenterBook Partners LP Invests $5.15 Million in ARS Pharmaceuticals, Inc. $SPRY
CenterBook Partners LP has acquired a new stake of 512,367 shares, valued at $5.15 million, in ARS Pharmaceuticals (NASDAQ:SPRY) during the third quarter, representing about 0.52% of the company. Other institutional investors like Vanguard Group Inc. and Aberdeen Group plc also increased their holdings. ARS Pharmaceuticals, which develops treatments for severe allergic reactions including anaphylaxis, currently has an average analyst rating of "Hold" and a consensus target price of $30.67.
How Ars Pharmaceuticals Inc. (SPRY) Affects Rotational Strategy Timing
The article analyzes Ars Pharmaceuticals Inc. (SPRY) using AI models, indicating weak sentiment across all time horizons and suggesting a short bias. It details three trading strategies: a long position trading strategy, a momentum breakout strategy, and a short risk hedging strategy. The analysis highlights an exceptional risk-reward short setup with a targeted 30.2% downside.
Needle-free epinephrine nasal spray may cut costs and boost patient preference
ARS Pharmaceuticals (Nasdaq: SPRY) is set to present new clinical and economic data for its neffy® (epinephrine nasal spray) at the 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting. The data highlights that neffy 2 mg provides similar exposure to a 0.5 mg intramuscular injection, offers a longer shelf life than autoinjectors, and shows increased patient preference due to needle aversion, potentially leading to cost savings and improved adherence. These insights suggest neffy could be a more affordable and preferred option for treating severe allergic reactions.
ARS Pharmaceuticals to Showcase Scientific Innovation and Accessibility: Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
ARS Pharmaceuticals will present robust clinical data on its epinephrine nasal spray, neffy®, at the 2026 AAAAI Annual Scientific Meeting. Five poster presentations and a case report will highlight the scientific innovation, real-world usability, and economic advantages of neffy® compared to traditional epinephrine auto-injectors. The company emphasizes neffy®'s potential for cost-effectiveness and patient preference due to its needle-free delivery and longer shelf life.
(SPRY) and the Role of Price-Sensitive Allocations
This article analyzes Ars Pharmaceuticals Inc. (NASDAQ: SPRY), highlighting weak sentiment across all horizons supporting a short bias. It details three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal analysis for near-term, mid-term, and long-term support and resistance levels.
SPRY SEC Filings - ARS Pharms 10-K, 10-Q, 8-K Forms
This page provides access to ARS Pharmaceuticals (SPRY) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights recent filings detailing financial results, financing agreements, and intellectual property developments, emphasizing the company's focus on epinephrine nasal spray products. The article also provides a list of recent Form 4 filings showing routine stock option grants to various directors.
How Investors Are Reacting To ARS Pharmaceuticals (SPRY) Expanded EU Pediatric Nod For Needle-Free Anaphylaxis Treatment
ARS Pharmaceuticals (SPRY) received a positive opinion from the EMA to expand the marketing authorization of its needle-free anaphylaxis treatment, EURneffy, to include a 1 mg nasal adrenaline spray for children in the EU, Iceland, Liechtenstein, and Norway. This expansion broadens the company's global reach and pediatric patient base, reinforcing the investment thesis that neffy can become a global standard of care. However, the stock's volatility, ongoing losses, and insider selling highlight financing and execution risks, with various analyst fair value estimates underscoring the wide range of expectations for the company's future performance.
ARS Pharma Gets Positive CHMP Opinion For 1 Mg EURneffy Nasal Spray
ARS Pharmaceuticals, Inc. (SPRY) received a positive opinion from the European Medicines Agency's CHMP for an expanded marketing authorization of EURneffy, their nasal adrenaline spray, to include a 1 mg dose for children weighing between 15 kg and less than 30 kg for emergency treatment of allergic reactions. This new opinion complements the existing approval for EURneffy 2 mg for adults and children 30 kg or more. The product is already commercially available in the U.S. and has been approved in several other countries.
Needle-free allergy rescue for kids wins key EU support
ARS Pharmaceuticals (SPRY) announced that the EMA CHMP has given a positive opinion for expanding the marketing authorization of EURneffy to include a 1 mg nasal adrenaline spray for emergency treatment of anaphylaxis in children weighing 15 kg to less than 30 kg. This recommendation complements the existing 2 mg approval for patients 30 kg and above, addressing a significant need for a needle-free option for younger children. Following European Commission approval, ALK-Abelló will distribute EURneffy across EU member states, Iceland, Liechtenstein, and Norway.
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
ARS Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization for EURneffy® (adrenaline nasal spray) to include a 1 mg dose for children in the EU weighing ≥15 kg to <30 kg. This decision means a needle-free option for anaphylaxis treatment will be available for younger children in the European Union, addressing a significant barrier to timely treatment. The 1 mg dose extends the existing approval for EURneffy 2 mg for adults and children weighing ≥30 kg, aiming to provide more families with access to an easy-to-use emergency treatment.
Lisanti Capital Growth LLC Sells 208,886 Shares of ARS Pharmaceuticals, Inc. $SPRY
Lisanti Capital Growth LLC has significantly reduced its stake in ARS Pharmaceuticals, Inc. by nearly 50% in the third quarter, selling 208,886 shares. The move comes as ARS Pharmaceuticals reported a quarterly EPS miss and maintains a negative net margin. While institutional investors own a substantial portion of the company, insiders have also been trimming their positions, yet analysts hold mixed views with a consensus target price of $33.00.
ARS Pharmaceuticals (NASDAQ:SPRY) Cut to Strong Sell at Zacks Research
Zacks Research has downgraded ARS Pharmaceuticals (NASDAQ:SPRY) from "hold" to "strong sell" following recent financial results where the company reported an EPS miss despite revenue beating estimates. The stock is trading near $10 with a market cap of approximately $994 million. Analyst coverage for SPRY is mixed, with an average "Hold" rating and a target price of $33.
OPDP doubles up on ARS’s Neffy
The FDA’s Office of Prescription Drug Promotion (OPDP) has issued a second warning letter to ARS Pharmaceutical Operations regarding its direct-to-consumer advertisement for Neffy (epinephrine nasal spray). The OPDP considers the ad "false or misleading" due to claims that overemphasize needle-free administration and suggest Neffy eliminates the need for other treatments or precautions for severe allergies. The warning also cited visual representations in the ad that contradict the product's approved labeling regarding storage.
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Moderate Buy" from Analysts
ARS Pharmaceuticals (NASDAQ:SPRY) has received a consensus "Moderate Buy" rating from analysts, with an average 1-year price target of $33.00, despite some recent insider selling and an EPS miss. The company, focused on developing treatments for severe allergic reactions, reported a revenue beat at $32.5M and has a market capitalization of $1.04 billion. Insider ownership stands at 33.5% and institutional investors hold 68.16% of the stock.
What ARS Pharmaceuticals (SPRY)'s neffyinSchools California Expansion Means For Shareholders
ARS Pharmaceuticals has expanded its neffyinSchools program to California, distributing free neffy epinephrine nasal spray to K–12 schools for emergency use. This expansion brings the program to 24 states, encompassing over 8,000 schools and nearly 45,000 donated doses. The move is viewed as a way to build long-term brand adoption for neffy in the education sector, rather than directly impacting short-term financials, while the company works towards profitability and broader market uptake.
What ARS Pharmaceuticals (SPRY)'s neffyinSchools California Expansion Means For Shareholders
ARS Pharmaceuticals (SPRY) has expanded its neffyinSchools program to California, offering free neffy epinephrine nasal spray to K–12 schools. This expansion, covering 24 states and over 8,000 schools, is seen as crucial for long-term brand adoption in emergency allergy care, though its immediate financial impact is limited. The company's investment narrative still relies on broader U.S. and international market uptake, payer coverage, and partnerships, while facing risks like unprofitability and stock volatility.
California K-12 schools get free needle-free epinephrine nasal spray
ARS Pharmaceuticals announced that California K-12 schools are now eligible for its neffyinSchools program, which provides free needle-free neffy® epinephrine nasal spray for emergency use. This expansion brings the program to 24 states with over 8,000 participating schools, aiming to empower school staff to quickly respond to severe allergic emergencies. To date, ARS Pharma has donated nearly 45,000 doses, offering eligible schools two cartons (four single-use doses) at no cost with replacements available.
Assessing ARS Pharmaceuticals (SPRY) Valuation After China Community Approval For Neffy Epinephrine Spray
ARS Pharmaceuticals (SPRY) saw its shares decline despite partner Pediatrix Therapeutics receiving approval for community use of neffy, an intranasal epinephrine spray, in China. This approval marks a significant market opportunity outside Chinese hospitals. The article suggests ARS Pharmaceuticals is 63.1% undervalued, with a narrative fair value of $28.83 against its current price of $10.63, driven by potential global expansion and revenue growth, though it cautions about concentration risk around a single product.
Assessing ARS Pharmaceuticals (SPRY) Valuation After China Community Approval For Neffy Epinephrine Spray
ARS Pharmaceuticals (SPRY) has gained investor attention after its partner Pediatrix Therapeutics received approval in China for community use of Neffy, an intranasal epinephrine spray. This approval opens a new market for ARS Pharmaceuticals, potentially leading to milestone payments and royalties. Despite recent share price declines, the company's long-term performance is strong, and a narrative valuation suggests the stock is undervalued at US$10.63 against a fair value of US$28.83, based on rapid revenue expansion and rising margins.
There's No Escaping ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) Muted Revenues Despite A 25% Share Price Rise
ARS Pharmaceuticals (NASDAQ:SPRY) has seen a 25% share price increase recently, contributing to a 16% rise over the last year. However, its Price-to-Sales (P/S) ratio of 9x remains below the industry average, largely due to forecasts predicting revenue growth of 45% annually for the next three years, which is significantly lower than the industry's projected 122% annual growth. This muted revenue outlook explains the company's lower P/S ratio and suggests shareholders are acknowledging a less prosperous future compared to industry peers.
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Catapults 25% Though Its Price And Business Still Lag The Industry
ARS Pharmaceuticals (NASDAQ:SPRY) recently saw its stock price jump 25% over the past month, contributing to a 16% rise over the last year. Despite this surge, its price-to-sales (P/S) ratio of 9x remains lower than the industry average, largely due to analyst forecasts predicting its revenue growth of 45% annually to lag the biotech industry's projected 122% growth. Investors' expectations of limited future growth appear to be the primary reason for the company's suppressed P/S ratio.
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock
ARS Pharmaceuticals Inc. (SPRY) stock surged after its competitor, Aquestive Therapeutics Inc. (AQST), received a negative update from the FDA regarding its Anaphylm New Drug Application. This FDA notification, which identified deficiencies precluding discussion of labeling and post-marketing commitments, is seen as a significant advantage for ARS Pharmaceuticals, as it removes or delays a potential competitor in the needle-free epinephrine space. Analysts believe this gives ARS more time to establish its product, neffy, as the leading needle-free option.
Why ARS Pharmaceuticals (SPRY) Is Down 6.0% After Winning China Approval For Neffy Allergy Spray
ARS Pharmaceuticals (SPRY) saw its stock drop 6.0% despite obtaining approval from China's National Medical Products Administration for its Neffy 2 mg epinephrine nasal spray for severe allergic reactions. This approval opens a large market in China, with a pediatric filing planned for further expansion, following a similar approval in Japan in 2025. The company's investment narrative heavily relies on Neffy's global expansion, managing its single-product dependence, and navigating potential pricing and reimbursement challenges in new markets.
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating
ARS Pharmaceuticals (SPRY) has received approval from China's NMPA for its epinephrine nasal spray, Neffy 2 mg, for the emergency treatment of severe allergic reactions in adults and children over 30 kg. Roth MKM reiterated a Buy rating with a $30 price target for SPRY following this development. ARS Pharma has an exclusive licensing agreement with Pediatrix Therapeutics for commercialization in China and expects to receive milestone payments and royalties.
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating
ARS Pharmaceuticals (SPRY) has received approval from China's National Medical Products Administration (NMPA) for Neffy, an epinephrine nasal spray for severe allergic reactions, leading Roth MKM to reiterate its Buy rating with a $30 price target. This approval, covering adults and children over 30 kg, comes with a licensing agreement with Pediatrix Therapeutics, including milestone payments and royalties for ARS Pharma. The company expects Neffy to be available in China by spring 2026 and plans to seek approval for a lower dose for younger children.
ARS Pharmaceuticals Stock Pre-Market (+4.4%) : 'neffy' Nasal Spray Approved in China
ARS Pharmaceuticals saw a pre-market stock increase of 4.4% following the approval of its 'neffy' nasal spray in China. This development marks a significant milestone for the company's international market expansion.
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Moderate Buy" by Brokerages
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 1-year price target of $31.80, suggesting significant upside from its current price of approximately $11.65. While the company recently missed EPS estimates, it exceeded revenue expectations with $32.5M. Insider selling has occurred, but institutional investors hold a substantial 68% of the stock.
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX?
Despite a typical year-end slowdown, the past week brought significant news in the biotech sector, including global approvals, clinical trial readouts, and strategic buyouts. Key highlights include ARS Pharma's Neffy gaining approval in China, Vanda Pharmaceuticals securing FDA approval for NEREUS, and setback for Outlook Therapeutics and Corcept with FDA Complete Response Letters. Additionally, InflaRx presented promising post-hoc data from a terminated Phase 3 trial, while SELLAS Life Sciences reported extended survival in its REGAL trial, and Ultragenyx and Genmab faced clinical development setbacks.
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX?
This article summarizes a busy week in biotech, detailing key global approvals such as ARS Pharma's Neffy in China and Vanda's NEREUS in the U.S. It also covers significant clinical trial news, including potential efficacy signals from InflaRx's Vilobelimab and continued progress for SELLAS Life Sciences, alongside setbacks for Ultragenyx and Genmab. Additionally, the article notes FONAR Corp.'s impending privatization.
ARS Pharmaceuticals Insiders Sold US$1.3m Of Shares Suggesting Hesitancy
Over the last year, insiders at ARS Pharmaceuticals (NASDAQ: SPRY) have sold US$1.3 million worth of shares, with Chief Business Officer Justin Chakma accounting for US$1.2 million of that amount. This significant selling activity, especially with no insider purchases reported, suggests potential hesitancy about the stock's current valuation despite high insider ownership of 9.5%. Investors are advised to consider these insider transactions and potential warning signs for the company.
ARS Pharmaceuticals Insiders Sold US$1.3m Of Shares Suggesting Hesitancy
Over the past year, insiders at ARS Pharmaceuticals have sold US$1.3 million worth of shares, notably Chief Business Officer Justin Chakma selling US$1.2 million, all of his holding, at a price below the current market value. This significant insider selling, without any corresponding purchases, raises questions about the insiders' confidence in the company's current valuation despite high insider ownership. Investors are advised to investigate further, considering this activity as a potential warning sign.
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 3.4% - Time to Buy?
ARS Pharmaceuticals (NASDAQ:SPRY) saw its shares rise by 3.4% during Monday's trading, closing at $11.7690, though trading volume was significantly below average. Analysts currently hold a "Moderate Buy" consensus rating with a target price of $31.80, suggesting substantial potential upside. Despite missing EPS estimates but beating revenue in the last quarter, insiders still maintain a significant ownership stake in the company.
Needle-free allergy rescue spray cleared in China for home use
ARS Pharmaceuticals received NMPA approval in China for neffy, its 2 mg epinephrine nasal spray, for emergency treatment of Type 1 allergic reactions in adults and children weighing over 30 kg, making it the first community-use epinephrine product approved in China. Commercialization rights are licensed to Pediatrix Therapeutics, with expected availability in spring 2026, generating a $4M milestone payment and potential sales milestones up to $80M for ARS Pharma. This approval expands neffy's global presence, following launches and approvals in the U.S., Europe, U.K., and Australia, and targets a large Chinese population at risk for severe allergic reactions.
Next Century Growth Investors LLC Makes New Investment in ARS Pharmaceuticals, Inc. $SPRY
Next Century Growth Investors LLC has made a new investment in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), purchasing over 622,000 shares worth approximately $10.87 million in Q2 2025. While analysts maintain a "Moderate Buy" rating with a target price significantly above the current stock price, the company remains unprofitable and recently missed EPS estimates, despite revenue beating expectations. Insider selling by COO Brian Dorsey and Justin Chakma has also been noted.
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8.1% - Here's What Happened
ARS Pharmaceuticals (NASDAQ:SPRY) saw its share price increase by 8.1% on Wednesday, trading at $9.77 with a significantly lower volume than average. The company faces financial challenges, having missed Q3 EPS estimates despite beating revenue expectations, remaining unprofitable, and experiencing recent insider stock sales. Analyst ratings are mixed, resulting in a "Moderate Buy" consensus but with a wide range of price targets.
ARS Pharmaceuticals (NASDAQ: SPRY) in fireside chat at Piper Sandler 37th Conference
ARS Pharmaceuticals will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. Company executives Richard Lowenthal and Eric Karas will engage in a fireside chat on December 3 at 2:30 pm ET with Piper Sandler analyst David Amsellem. The company's stock, SPRY, saw a 3.13% gain reflecting a positive market reaction on the news' publication day, adding approximately $28M to its valuation.
ARS Pharmaceuticals, Inc. to Participate in Piper Sandler 37th Annual Healthcare Conference
ARS Pharmaceuticals, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. CEO Richard Lowenthal and CCO Eric Karas will engage in a fireside chat on December 3 at 2:30 pm ET and hold one-on-one investor meetings. The company, known for its epinephrine nasal spray neffy®, aims to enhance visibility and discuss its strategic vision in the biopharmaceutical market.
ARS Pharmaceuticals, Inc. to Participate in Piper Sandler 37th Annual Healthcare Conference | SPRY Stock News
ARS Pharmaceuticals, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, in New York. Co-Founder and CEO Richard Lowenthal and Chief Commercial Officer Eric Karas will have a fireside chat on December 3, and the company will hold one-on-one investor meetings. The event aims to enhance visibility for ARS Pharma, which focuses on empowering at-risk patients with its epinephrine nasal spray, neffy®, for allergic reactions.
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
ARS Pharmaceuticals, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. Richard Lowenthal, Co-Founder, President and CEO, and Eric Karas, Chief Commercial Officer, will conduct a fireside chat on December 3 at 2:30 pm ET, and company management will also hold one-on-one investor meetings. A live webcast of the chat will be available on the company's website.
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
ARS Pharmaceuticals, Inc. announced its participation in the Piper Sandler 37th Annual Healthcare Conference, taking place December 2-4, 2025, in New York. Richard Lowenthal, Co-Founder, President and CEO, and Eric Karas, Chief Commercial Officer, will participate in a fireside chat on December 3 at 2:30 pm ET. The company will also hold one-on-one meetings with investors to discuss neffy®, its epinephrine nasal spray for allergic reactions.
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
ARS Pharmaceuticals, Inc. announced its Q3 2025 financial results, reporting $32.5 million in revenue, largely from neffy U.S. net product sales. The company highlighted significant progress in neffy's commercial launch and global expansion, including increased patient awareness, HCP adoption, and regulatory approvals in Japan and the UK, while maintaining a strong cash position to fund operations through cash-flow break-even.
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
ARS Pharmaceuticals, Inc. announced it will present real-world data on its intranasal epinephrine spray, neffy®, at the 2025 ACAAI Annual Scientific Meeting. The presentations will include a late-breaking oral presentation and six poster presentations highlighting the effectiveness and real-world impact of neffy in various clinical settings and patient populations. This data aims to demonstrate neffy's reliable effectiveness for treating anaphylaxis, comparable to epinephrine injections, while offering a needle-free administration method.
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
ARS Pharmaceuticals, Inc. announced it will host a conference call and webcast on Monday, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its third quarter 2025 financial results and business highlights. The company is focused on commercializing neffy® (epinephrine nasal spray) for the emergency treatment of Type I allergic reactions, including anaphylaxis. A replay of the webcast will be available for 30 days following the event.
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
ARS Pharmaceuticals announced that the European Patent Office upheld the validity of all claims in a key patent related to its neffy® epinephrine nasal spray, ensuring intellectual property coverage until at least 2039. This favorable decision follows a successful defense of a similar patent challenge in the U.S., reinforcing the strength of the company's global patent portfolio for intranasal epinephrine. neffy® is an emergency treatment for allergic reactions, including anaphylaxis, in adults and children aged 4 years and older.
ARS Pharmaceuticals: 'Betting On The Come' (NASDAQ:SPRY)
ARS Pharmaceuticals is highlighted for its Neffy product, the first non-injectable epinephrine for severe allergic reactions, which presents a first-mover advantage and strong global market potential. The company targets extensive U.S. commercial coverage and international expansion with a robust financial position, including significant cash reserves and no long-term debt, supported by a lucrative licensing deal. This article provides an updated analysis of SPRY stock, emphasizing its growth prospects.
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity
RA Capital Management has provided an initial $100 million investment to ARS Pharmaceuticals, Inc. to support the expansion of commercial activity for _neffy_, a nasal spray for allergic reactions. This financing is part of RA Capital's new Structured Capital strategy, which offers flexible financing solutions to innovative healthcare companies. The investment aims to accelerate the adoption of _neffy_ and leverage RA Capital's comprehensive support for its portfolio companies.
Firm Advises ARS Pharma on Patent Matters Related to Loan Facility Up to $250 Million
Wilson Sonsini Goodrich & Rosati advised ARS Pharmaceuticals, Inc. on patent matters related to a senior secured term loan facility of up to $250 million. The facility, entered into with affiliates of RA Capital Management and OMERS Life Sciences, will provide an initial $100 million to accelerate the commercial growth of neffy®, ARS Pharma's nasal spray for allergic reactions. The funding will also support marketing and medical affairs initiatives for neffy.
Firm Helps Secure Favorable Decision from European Patent Office on Behalf of ARS Pharmaceuticals
Wilson Sonsini helped ARS Pharmaceuticals, Inc. secure a favorable decision from the European Patent Office (EPO). The EPO's Opposition Division upheld the validity of all claims in EP 3678649, a patent related to neffy® (epinephrine nasal spray) which is validated in over 30 European countries. This decision extends ARS Pharma’s global intellectual property protection for neffy until at least 2039.
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
ARS Pharmaceuticals, Inc. has secured a senior secured term loan facility of up to $250 million from affiliates of RA Capital Management and OMERS Life Sciences. An initial $100 million has been drawn to accelerate the commercial growth of neffy®, a needle-free epinephrine nasal spray for allergic reactions. This funding aims to boost market share by expanding prescriber bases across various medical fields and supporting marketing efforts, without shareholder dilution.
